Polynovo Limited (ASX:PNV)

$1.37

right-arrow Created with Sketch. -0.035 (-2.49%)
MCAP $929.2M
Last trade 16.10pm 06/12/2021 20mins delayed

Latest Announcements

12/11/2021PNVPolynovo Limited
09/11/2021PNVPolynovo Limited
05/11/2021 Price SensitivePSPNVPolynovo Limited
05/11/2021PNVPolynovo Limited
04/11/2021PNVPolynovo Limited
29/10/2021 Price SensitivePSPNVPolynovo Limited
26/10/2021PNVPolynovo Limited
26/10/2021 Price SensitivePSPNVPolynovo Limited

Company Overview

PolyNovo Limited is an Australia-based medical devices company. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. It can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.

PNV in the news

PolyNovo (PNV) enrols the first patient in the trial of its dermal…
Despite COVID-19 limiting access to hospitals and surgeons, PolyNovo (PNV) records increasing…
Medical device company PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director…
PolyNovo (PNV) has signed deal with group purchasing organisation Premier for the…

Search Previous Announcements